Posted by Michael Wonder on 08 Aug 2020
U.S. Food and Drug Administration approves Lampit (nifurtimox) for the treatment of Chagas disease in children
7 August 2020 - Only Chagas disease treatment approved in U.S. for use in children from birth to less than 18 years of age.
Bayer announced today that the United States FDA has approved Lampit (nifurtimox) for use in paediatric patients (from birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi (T. cruzi).
Lampit, an anti-protozoal medication will be available in a new, dividable tablet that can be split on the scored lines by hand. According to prescribing instructions, the tablet is specially formulated to disperse in water, which can aid in the dosing and administration to paediatric patients who may have difficulty swallowing whole or half tablets.
